Guideline for Tapering Glucocorticoids After Prolonged Therapy

Duration‑Based Approach

• Short courses (< 3–4 weeks) can be stopped abruptly without tapering, regardless of the glucocorticoid dose, and adrenal insufficiency testing is unnecessary. This applies even when high doses are used for acute conditions such as asthma exacerbations. 1
• For therapy lasting ≥ 3–4 weeks, the underlying disease must be adequately controlled before initiating a taper. 1

Dose‑Based Tapering Strategy

Supraphysiologic Range (> 30 mg prednisone‑equivalent)

• Taper rapidly using larger dose decrements; this reduces cumulative glucocorticoid exposure and associated side‑effects. No adrenal function testing is required while in this range. 1

Intermediate Range (15–30 mg prednisone‑equivalent)

• Adopt a moderate taper speed with medium‑sized decrements and begin routine monitoring for glucocorticoid‑withdrawal syndrome. 1

Approaching Physiologic Doses (4–6 mg prednisone‑equivalent)

• Switch to a dramatically slower taper using small decrements; this is the critical zone where hypothalamic‑pituitary‑adrenal (HPA) axis recovery becomes relevant. Consider converting from long‑acting agents (e.g., dexamethasone) to shorter‑acting agents (e.g., hydrocortisone or prednisone). 1

Assessment at Physiologic Doses

• Option 1 – Clinical Monitoring: Continue a gradual taper while vigilantly observing for signs of adrenal insufficiency (fatigue, weakness, nausea, hypotension, hypoglycemia). 1
• Option 2 – Morning Serum Cortisol Testing (drawn before the daily glucocorticoid dose):
   > 300 nmol/L (≈10 µg/dL) → HPA axis recovered; glucocorticoid can be stopped.
   150–300 nmol/L (5–10 µg/dL) → Maintain physiologic dose and repeat testing in weeks‑to‑months.
  * < 150 nmol/L (<5 µg/dL) → Continue physiologic dose and retest after several months. 1

Critical Safety Considerations

• HPA‑axis suppression is expected in any patient receiving > 7.5 mg prednisone‑equivalent daily for > 3 weeks; these patients require education on stress‑dosing. 3
• During intercurrent illness, increase the glucocorticoid dose for three days or switch to intravenous hydrocortisone (e.g., 25 mg twice daily for patients on 10 mg prednisone; 50 mg three times daily for high‑dose therapy). 3

Glucocorticoid‑Withdrawal Syndrome

• Distinguish withdrawal syndrome from true adrenal insufficiency; typical symptoms include myalgias, arthralgias, malaise, and mood changes. If severe, temporarily raise the dose to the last tolerated level and extend the taper duration. This diagnosis is clinical and separate from biochemical adrenal insufficiency. 1

Common Pitfalls to Avoid

• Do not perform routine adrenal‑insufficiency testing while patients are on supraphysiologic doses; the pre‑test probability of suppression is near 100 % and testing adds no clinical value. 1
• Avoid rapid tapering once the dose is in the physiologic range (4–6 mg prednisone‑equivalent), as this period carries the highest risk of adrenal crisis. 1
• Before initiating a taper, assess and manage comorbidities such as diabetes, hypertension, osteoporosis, and infection risk. 3
• Do not employ alternate‑day therapy as a tapering strategy; it does not reliably prevent HPA‑axis suppression. 3

Special Circumstances

• In patients experiencing severe glucocorticoid‑related complications (e.g., uncontrolled hyperglycemia, psychosis, herpetic keratitis), a more rapid taper toward physiologic doses may be warranted, balancing the need to reduce exposure against the risk of adrenal crisis. 2

Patient‑Education Requirements

• All patients must be instructed on stress‑dosing protocols for acute illness, surgery, or trauma. Provide written instructions and ensure primary‑care providers and the broader treatment team are aware of the patient’s glucocorticoid history. 3